Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03385239 · ClinicalTrials.gov registry record · Phase 2
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
A Phase 2 study, sponsored by Akcea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT03385239 is a Phase 2 study that has completed, run by Akcea Therapeutics. The registered enrollment target is 114 participants.
The verdict
NCT03385239, a Phase 2 study, has completed, sponsored by Akcea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.
Interventions
- DRUG Placebo
- DRUG ISIS 678354
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03385239
The ClinicalTrials.gov registry entry for NCT03385239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akcea Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03385239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03385239 about?
NCT03385239 is a clinical study titled "Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)". This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants wit...
What is the current status of trial NCT03385239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-01-30. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT03385239?
The interventions under investigation include: Placebo (DRUG), ISIS 678354 (DRUG).
Who is sponsoring clinical trial NCT03385239?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.